Physician profile
Jose Derdoy
NPI 1396838876
$5,636.99
in general payments reported to CMS, 2019-2025
9 companies · $5,300 in 2025
The $5,300 reported for 2025 was more than what 91% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.64 · 2021: $12.04 · 2022: $45.66 · 2023: $230 · 2025: $5,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,300 · Food and Beverage: $207 · Education: $23.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,300.00 |
| Food and Beverage | $206.54 |
| Education | $23.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $5,300.00 | 2025 | Capsocam Colon |
| Genzyme Corporation | $136.94 | 2023 | |
| Qol Medical, LLC | $52.23 | 2019-2023 | Sucraid |
| Travere Therapeutics, INC. | $47.86 | 2022-2023 | Cholbam |
| Takeda Pharmaceuticals U.S.A., INC. | $37.84 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.57 | 2023 | |
| Fresenius Kabi USA, LLC | $17.13 | 2019 | |
| Janssen Biotech, INC. | $14.38 | 2023 | Stelara, Remicade, Simponi Aria |
| Abbvie INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Derdoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.